TriSalus Life Sciences, Inc. specializes in innovative drug delivery technology, chiefly its TriNav family of PEDD infusion systems designed to treat challenging liver and pancreatic cancers. The company has demonstrated solid revenue growth driven by broader market adoption of newly launched TriNav devices, supported by permanent CMS reimbursement codes. However, it continues to report significant operating losses and negative cash flows amid ongoing R&D investments and operational scale-up costs. TriSalus relies heavily on third-party manufacturers, heightening supply chain vulnerabilities and regulatory compliance risks. Future growth depends on expanding addressable markets through product innovation and clinical trials while managing capital constraints and competitive pressures.